Mirkiewicz-Sieradzka B, Zygulska-Mach H, Romanowska B, Bryk J, Heitzman J, Ksiezyk M
Katedry i Kliniki Okulistyki Collegium Medicum UJ w Krakowie.
Klin Oczna. 1999;101(4):287-90.
The problem of orbit irradiation after enucleation of the eye with choroidal melanoma is controversial. We have decided to analyse our own material in order to estimate the effectiveness of this method.
The clinical material comprised 202 patients, 97 women and 105 men, in the age of 15-84 years, whose eyeballs were enucleated because of choroidal melanoma. In 72 patients the orbit was irradiated after enucleation with 60Co applicator (CKA4). The dose was about 50 Gy, 5 mm deep. The height of tumour, its location, histological type, infiltration of the sclera or beyond the eyeball and the treatment of tumour before enucleation were analysed. The follow-up time was 5-20 years.
The survival time of patients in the age below 30 years (p < 0.05) and of patients with choroidal melanoma of the height above 3 mm (p < 0.01) was significantly longer when the orbit was irradiated. Also the survival time of patients with scleral infiltration and with spindle-cell type of tumour was longer (but statistically not significantly) in those, whose orbits were irradiated after enucleation. Exenteration of the orbit was necessary in 4 cases not irradiated after enucleation, only in 1 case after irradiation. The probability of survival after irradiation of the orbit was significantly higher than in cases not irradiated (0.6971 vs. 0.6219). The estimated mean survival time (in months) was longer, but not significantly, in patients after irradiation of the orbit (197.017 vs. 181.409). We conclude that irradiation of the orbit after enucleation of the eye with choroidal melanoma should be recommended. Further investigations will be continued with collaboration of Institute of Oncology in Cracow.
眼球摘除术后脉络膜黑色素瘤眼眶照射的问题存在争议。我们决定分析我们自己的病例资料,以评估该方法的有效性。
临床资料包括202例患者,其中97例女性,105例男性,年龄在15 - 84岁之间,因脉络膜黑色素瘤行眼球摘除术。72例患者在眼球摘除术后用60钴施源器(CKA4)进行眼眶照射。剂量约为50 Gy,深度5 mm。分析了肿瘤高度、位置、组织学类型、巩膜浸润或眼球外浸润情况以及眼球摘除术前的肿瘤治疗情况。随访时间为5 - 20年。
眼眶照射组30岁以下患者(p < 0.05)以及肿瘤高度大于3 mm的脉络膜黑色素瘤患者(p < 0.01)的生存时间显著更长。眼球摘除术后眼眶照射的巩膜浸润患者和梭形细胞型肿瘤患者的生存时间也更长(但无统计学意义)。眼球摘除术后未照射的4例患者需要行眼眶内容物剜除术,而照射后仅1例需要。眼眶照射后的生存概率显著高于未照射组(0.6971对0.6219)。眼眶照射患者的估计平均生存时间(以月计)更长,但无显著差异(197.017对181.409)。我们得出结论,脉络膜黑色素瘤眼球摘除术后应推荐眼眶照射。将与克拉科夫肿瘤研究所合作继续进行进一步研究。